Corbus Pharmaceuticals (CRBP) vs Immunic (IMUX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunic (IMUX) has outperformed Corbus Pharmaceuticals (CRBP) over the past year, losing 15.8% versus a loss of 60.7%. Over five years, CRBP leads with a -82.8% price change compared with -91.3% for IMUX. Immunic is the larger company by market cap ($103.2 million vs $101.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRBP | IMUX |
|---|---|---|
| Share price | $5.27 | $7.56 |
| Market cap | $101.93M | $103.15M |
| 1-day change | -4.01% | -0.92% |
| YTD return | -35.26% | +41.57% |
| 1-year return | -60.73% | -15.81% |
| 5-year return | -82.78% | -91.28% |
| EPS (TTM) | $-6.11 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $20.56 | $17.43 |
| 52-week low | $5.13 | $5.06 |
| Distance from 52-week high | -74.37% | -56.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +545.73% | +469.97% |
| Average volume | 756.54K | 284.68K |
| Shares outstanding | 19.34M | 13.64M |
| Employees | 36 | 100 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMUX has outperformed CRBP by 44.9 percentage points over the past year.
About Corbus Pharmaceuticals
CRBP stock →Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity.
Healthcare · Biotechnology · 36 employees
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Healthcare · Biotechnology · 100 employees
CRBP vs IMUX FAQ
Which is bigger, Corbus Pharmaceuticals or Immunic?
Immunic (IMUX) is larger, with a market capitalization of $103.15M compared with $101.93M for Corbus Pharmaceuticals (CRBP).
Which stock has performed better over the past year, CRBP or IMUX?
IMUX returned -15.81% over the past 12 months, compared with -60.73% for CRBP (price return, excluding dividends). Past performance does not predict future results.
Are Corbus Pharmaceuticals and Immunic in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.